NASH - NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NASH - NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NASH - NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NASH - NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug HPG1860 shows promise in reducing liver fat in NASH patients
Disease control CompletedThis study tested three different doses of HPG1860, an experimental oral drug, against a placebo in 89 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. The main goals were to check safety and see if the drug could lower liver fat content measured by…
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Hepagene (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug shows promise for reversing liver damage in NASH patients
Disease control CompletedThis study tested a new drug called BIO89-100 (Pegozafermin) in 222 adults with NASH, a serious fatty liver disease with liver scarring. Participants received weekly injections of the drug or a placebo for about 6 months. The goal was to see if the drug could reduce liver inflamm…
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: 89bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Fatty liver drug shows promise in small trial
Disease control CompletedThis pilot study tested a drug called ibutamoren in 12 adults with nonalcoholic fatty liver disease (NAFLD). The goal was to see if it could lower fat in the liver. Participants took the drug for 6 months, and researchers measured liver fat using special MRI scans. The study was …
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New blood test could end painful liver biopsies for millions
Diagnosis CompletedThis study tested a new blood test called LLIFT to see if it can accurately diagnose fatty liver disease and its severe form, NASH, without needing a liver biopsy. Researchers enrolled 158 people at high risk for metabolic syndrome. The LLIFT test combines patient information lik…
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Sponsor: University Hospital, Lille • Aim: Diagnosis
Last updated Jun 27, 2026 08:06 UTC
-
Can a phone app help fight fatty liver disease?
Knowledge-focused CompletedThis study tested whether a mobile health app called EL-FIT could help people with nonalcoholic steatohepatitis (NASH) exercise safely at home. Seventeen adults with NASH used the app and a Fitbit to do daily exercise as they wished. The main goal was to see if it was feasible an…
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New Free-Breathing MRI could make liver scans easier for kids
Knowledge-focused CompletedThis study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and t…
Matched conditions: NASH - NONALCOHOLIC STEATOHEPATITIS
Sponsor: University of California, Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC